5-HT1A receptor knockout mice and mice overexpressing corticotropin-releasing hormone in models of anxiety

被引:72
作者
Groenink, L
Pattij, T
De Jongh, R
Van der Guten, J
Oosting, RS
Dirks, A
Olivier, B
机构
[1] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Psychopharmacol, NL-3584 CA Utrecht, Netherlands
[2] Radboud Univ Nijmegen Med Ctr, Dept Anat, Nijmegen, Netherlands
[3] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA
关键词
anxiety-; 5-HT1A receptor; CRF (corticotropin-releasing factor); CRH (corticotropin-releasing hormone); transgenic; knockout;
D O I
10.1016/S0014-2999(03)01281-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmacological experiments have implicated a role for serotonin (5-HT)(1A) receptors in the modulation of anxiety. More recent is the interest in corticotropin-releasing hormone (CRH) system as a potential target for the treatment of anxiety disorders. However, selective pharmacological tools for the CRH system are limited, hampering research in this field. Gene targeting is a relatively new approach to study mechanisms underlying anxiety disorders. 5-HT1A receptor knockout (1AKO) mice have been created on three different background strains, and two different lines of mice, overexpressing CRI-I (CRH-OE), have been generated. In the present review, behavioural and physiological findings reported for I AKO mice and CRH-OE mice will be reviewed. As behavioural. phenotyping is often limited to one or two approach avoidance paradigms, we extended these observations and also tested 1AKO and CRH-OE mice in a conditioned fear paradigm. This paradigm reflects essentially different aspect of anxiety than approach avoidance paradigms. 1AKO mice on a 129/Sv background strain showed similar freezing as wild-type (WT) mice. In CRH-OE mice, less freezing was observed than in the corresponding wild-type mice. The fact that the anxious phenotype of these genetically altered mice seems less clear than initially reported will be discussed. Rather than studying the direct consequences of alterations in the targeted gene, 1AKO and CRH-OE mice seem very valuable to study compensatory processes that seem to have taken place in reaction to life-long changes in gene expression. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:185 / 197
页数:13
相关论文
共 89 条
[1]   EFFECTS OF REPEATED ADMINISTRATION OF CORTICOTROPIN-RELEASING FACTOR ON SCHEDULE-CONTROLLED BEHAVIOR IN RATS [J].
AHLERS, ST ;
SALANDER, MK .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1993, 44 (02) :375-380
[2]   METALLOTHIONEIN GENE-EXPRESSION AND METAL REGULATION DURING PREIMPLANTATION MOUSE EMBRYO DEVELOPMENT (MT MESSENGER-RNA DURING EARLY DEVELOPMENT) [J].
ANDREWS, GK ;
HUETHUDSON, YM ;
PARIA, BC ;
MCMASTER, MT ;
DE, SK ;
DEY, SK .
DEVELOPMENTAL BIOLOGY, 1991, 145 (01) :13-27
[3]   IMMUNOREACTIVE CORTICOTROPIN-RELEASING HORMONE IN THE HYPOTHALAMOINFUNDIBULAR TRACT [J].
ANTONI, FA ;
PALKOVITS, M ;
MAKARA, GB ;
LINTON, EA ;
LOWRY, PJ ;
KISS, JZ .
NEUROENDOCRINOLOGY, 1983, 36 (06) :415-423
[4]   The role of corticotropin-releasing factor in depression and anxiety disorders [J].
Arborelius, L ;
Owens, MJ ;
Plotsky, PM ;
Nemeroff, CB .
JOURNAL OF ENDOCRINOLOGY, 1999, 160 (01) :1-12
[5]   EFFECTS OF CORTISOL TREATMENT ON BRAIN AND ADRENAL CORTICOTROPIN-RELEASING HORMONE (CRH) CONTENT AND OTHER PARAMETERS REGULATED BY CRH [J].
BAGDY, G ;
CALOGERO, AE ;
SZEMEREDI, K ;
CHROUSOS, GP ;
GOLD, PW .
REGULATORY PEPTIDES, 1990, 31 (02) :83-92
[6]   Corticotropin-releasing hormone and animal models of anxiety: Gene-environment interactions [J].
Bakshi, VP ;
Kalin, NH .
BIOLOGICAL PSYCHIATRY, 2000, 48 (12) :1175-1198
[7]   A review of central 5-HT receptors and their function [J].
Barnes, NM ;
Sharp, T .
NEUROPHARMACOLOGY, 1999, 38 (08) :1083-1152
[8]  
Behan DP, 1996, MOL PSYCHIATR, V1, P265
[9]   Measuring normal and pathological anxiety-like behaviour in mice: a review [J].
Belzung, C ;
Griebel, G .
BEHAVIOURAL BRAIN RESEARCH, 2001, 125 (1-2) :141-149
[10]   The genetic basis of the pharmacological effects of anxiolytics: a review based on rodent models [J].
Belzung, C .
BEHAVIOURAL PHARMACOLOGY, 2001, 12 (6-7) :451-460